Page URL:

Human trials of ES cell research could begin soon

23 November 2009
Appeared in BioNews 535

Stem cell therapy came one step closer to being tested for the first time in people this week, as a US company applied to the Food and Drug Administration (FDA) for a licence to start a clinical trial. The embryonic stem cell (ES cell) therapy is being developed to treat Stargardt, a currently incurable disease that causes blindness in young people.

Advanced Cell Technology, a Massachusetts-based firm, has tested the treatment on rats and mice which model the human Stargardt disease, and found it prevented further vision loss without adverse side effects.

Stargardt's macular degeneration destroys a part of the retina, leading to loss of vision. The treatment involves a single injection of a type of retinal cell that supports the photoreceptors needed for vision. The researchers have generated the retinal cells from ES cells derived from day-old human embryos left over from IVF treatment and donated for research purposes. ES cells have the potential to develop into any type of cell in the body and, as such, scientists envisage they could be used to mend any broken part of the body, from kidney and liver to brain. They hold promise as a treatment for a range of diseases from Parkinson's to heart disease. However, using ES cells in medical research is controversial as many view the embryo as sacrosanct and inviolable, and oppose the use of human embryos in research.

'After years of research and political debate, we're finally on the verge of showing the potential clinical value of embryonic stem cells,' said Dr Robert Lanza, the chief scientific officer at Advanced Cell Technology. He added: 'We've seen absolutely no adverse effects whatsoever in any of the preclinical experiments and our cells are more than 99.9 per cent pure.'

'Our research clearly shows that stem cell-derived retinal cells can rescue visual function in animals that otherwise would have gone blind. We are hopeful that the cells will be similarly efficacious in patients,' Dr Lanza continued.

The trials would involve 12 Stargardt patients, and could begin early next year if the FDA grants approval. The clinical trial could be the first in the world as US company Geron, the only company so far to have received a licence from the FDA, has delayed the start of its clinical trial until the end of next year due to safety problems.

A similar proposal to treat age-related macular degeneration with ES cells is being developed by scientists in the UK led by Professor Pete Coffey of University College London, but this clinical trial is unlikely to start until early 2011.

Company seeks FDA permission to conduct clinical trial using human embryonic stem cells
LA Times |  19 November 2009
Embryonic stem cells to cure eye disease
Nature blogs |  19 November 2009
First human trials for stem cell blindness therapy
The Daily Telegraph |  20 November 2009
Huge potential balanced against ethical fears
The Independent |  20 November 2009
People facing blindness may pioneer stem-cell therapy
The Times |  20 November 2009
Stem cells: the first human trial
The Independent |  20 November 2009
12 September 2011 - by Rosie Beauchamp 
An Australian company has announced it has received regulatory approval from the European Medicines Agency (EMA) to begin phase II trials for its cardiovascular stem cell treatment, Revascor....
2 August 2010 - by Dr Marianne Kennedy 
Biotechnology company Geron has been given the all clear for the world's first clinical trial involving human embryonic stem cells (hESCs). This comes a year after the US Food and Drug Administration (FDA) placed the study on hold amid safety fears...
7 June 2010 - by Louise Mallon 
Researchers have developed a method of creating large amounts of human embryonic stem (ES) cells using a new technique, which could help to treat a variety of diseases, according to new research published in the journal Nature Biology....
8 November 2009 - by Dr Jay Stone 
American company Geron Corporation (GC) has been given permission to resume its clinical trials testing the embryonic stem cell treatment GRNPOC1....
28 September 2009 - by Dr Marianne Kennedy 
The US Food and Drug Administration (FDA) has granted approval to NeuralStem Inc., a Maryland-based biotherapeutics company, to conduct the first human trial using neural stem cells for treatment of amyotrophic lateral sclerosis (ALS). ALS is a type of motor neuron disease often referred to as 'Lou Gehrig's' and 'Maladie de Charcot'. The late-onset condition, of unknown cause, affects approximately two in 100,000 people, including the UK physicist Stephen Hawking and US rock gui...
6 September 2009 - by Nishat Hyder 
Information has come to light regarding the US Food and Drug Adminstration (FDA)'s freeze on the clinical trails of GRNOPC1, a groundbreaking therapy for spinal cord injury derived from human embryonic stem cells (ES cells) being undertaken by biotech company Geron...
23 August 2009 - by Alison Cranage 
The US Food and Drug Administration (FDA) has delayed the start of a clinical trial that plans to use human embryonic stem cell(ES) cells to treat spinal cord injury. The trial is being run by Californian based company Geron. The FDA originally gave the go-ahead for the trial in January, but now has halted the start in order to review new data submitted by Geron....
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.